The Orphan Drug designation was supported by data from an open-label phase 2 trial that included 8 adult patients with mild to moderate Behçet disease and active oral and/or genital ulcers. The Food ...

The MarketWatch News Department was not involved in the creation of this content. -- Study results support advancing SGX945 in this difficult-to-treat orphan disease -- Results suggest potential ...

Researchers identified 7 distinct phenotypic clusters among pediatric patients with Behçet disease, with manifestations varying based on geography and system involvement. Findings from an ...

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Behçet's disease is a complex, multisystem inflammatory disorder characterised by recurrent mucocutaneous lesions, ocular involvement, and vascular, neurological, and gastrointestinal manifestations.

LIVERPOOL, ENGLAND — The British Society for Rheumatology (BSR) and the British Association of Dermatologists (BAD) have joined forces for the first time to develop the first British guidelines for ...

Soligenix (NASDAQ: SNGX) announced that SGX945 (dusquetide) has received Promising Innovative Medicine ("PIM") designation ...

Behçet's disease (BD) is a multisystem inflammatory disorder currently classified as a vasculitis. Its etiopathogenesis is unclear, but environmental, genetic and autoimmune factors have been ...

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy The Phase 2a study, evaluating control of oral ...

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...